期刊
AMERICAN JOURNAL OF MEDICINE
卷 123, 期 4, 页码 -出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.amjmed.2009.07.017
关键词
Diabetes mellitus; Drug toxicity; Risk assessment; Safety; Therapeutics
资金
- Amylin Pharmaceuticals, Inc.
The selection of appropriate pharmacologic therapy for any disease requires a careful assessment of benefit and risk. In the case of type 2 diabetes, this decision typically balances the benefits accrued from improved glycemic control with the risks inherent in glucose-lowering medications. This review is intended to assist therapeutic decision-making by carefully assessing the potential benefit from improved metabolic control relative to the potential risks of a wide array of currently prescribed glucose-lowering agents. Wherever possible, risks and benefits have been expressed in terms of absolute rates (events per 1000 patient-years) to facilitate cross-study comparisons. The review incorporates data from new studies (Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation, Action to Control Cardiovascular Risk in Diabetes, and the Veterans Affairs Diabetes Trial), as well as safety issues associated with newer glucose-lowering medications. (C) 2010 Elsevier Inc. All rights reserved. The American Journal of Medicine (2010) 123, 374.e9-374.e18
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据